End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
34.94 CNY | +0.32% | -2.35% | +22.08% |
Strengths
- With a P/E ratio at 10.99 for the current year and 9.88 for next year, earnings multiples are highly attractive compared with competitors.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+22.08% | 3.64B | C+ | ||
+17.35% | 71.39B | C+ | ||
+2.39% | 25.1B | C+ | ||
-1.22% | 8.59B | C | ||
+6.69% | 8.19B | B | ||
-20.96% | 7.91B | B- | ||
-0.24% | 4.54B | B- | ||
+17.12% | 4.31B | B+ | ||
-2.61% | 3.86B | B | ||
+7.96% | 3.29B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 600511 Stock
- Ratings China National Medicines Corporation Ltd.